Search Results for "Zytiga Medicare Payment Of"
Matching Channels
On April 28, 2011, the US Food and Drug Administration (FDA) approved Zytiga (abiraterone acetate), for use in combination with prednisone for the second-line treatment of castration-resistant prost...
What is new in prostate cancer research and development?
Key research areas in relation to Prostate Cancer are discussed below. Brief descriptions are supported by hyperlinks to the most relevant research papers and current affairs news reports and...
Matching News
Zytiga pre-chemo data published
Having secured the US FDA's blessing for an expanded label for Zytiga (abiraterone), Janssen has now published the data from the COU-AA-302 study, which formed the basis of that approval. Earlier this...
A survey by the Medical Group Management Association concluded that physicians' willingness to try new models of payment and delivery -- such as accountable care organizations and bundled payments --...
Johnson & Johnson files for new Zytiga approval
Johnson & Johnson said Friday it has asked U.S. and European Union regulators to grant broader marketing approval for its cancer pill Zytiga.Zytiga was approved in 2011 for the treatment of advanced...
Johnson & Johnson files for new Zytiga approval
Johnson & Johnson said Friday it has asked U.S. and European Union regulators to grant broader marketing approval for its cancer pill Zytiga.Zytiga was approved in 2011 for the treatment of advanced...
Extended Use Of Zytiga Approved By FDA For Late-Stage Prostate Cancer
Today the U.S. Food and Drug Administration (FDA) lengthened the approved use of Zytiga (abiraterone acetate) as treatment for men with late-stage, castration-resistant prostate cancer (metastatic) be...
House Committee Asks for AAFP Input on Solving Payment Problem
For the second year in a row, a key congressional committee has formally solicited the AAFP's views on ways to improve the quality and efficiency of the Medicare physician payment system, and the Acad...
Report: Medicare payment instability keeps practices from trying new models
Fears of sustainable growth rate payment cuts and instability in Medicare payments are keeping many physician practices from participating in new payment delivery models or demonstration programs,...
AAFP Provides Members With Medicare Options as Payment Cuts Loom
To date, Congress and the White House have failed to reach an agreement to avert Medicare payment reductions scheduled to take effect on Jan. 1 and 2. In response, the AAFP has updated its information...
Matching PubMed Articles
Medicare program; end-stage renal disease prospective payment system. Final rule.
This final rule implements a case-mix adjusted bundled prospective payment system (PPS) for Medicare outpatient end-stage renal disease (ESRD) dialysis facilities beginning January 1, 2011 (ESRD PPS),...
Perceived impact of the Medicare policy to adjust payment for health care-associated infections.
In 2008, the Centers for Medicare and Medicaid Services (CMS) ceased additional payment for hospitalizations resulting in complications deemed preventable, including several health care-associated inf...
Qu H, Shewchuk RM, Chen Y, Deutsch A. Impact of Medicare prospective payment system on acute rehabilitation outcomes of patients with spinal cord injury.
Medicare Payment Reform and Provider Entry and Exit in the Post-Acute Care Market.
OBJECTIVE: To understand the impacts of Medicare payment reform on the entry and exit of post-acute providers. DATA SOURCES: Medicare Provider of Services data, Cost Reports, and Census data from 1991...
Medicare Payment Reform - Proposals for Paying for an SGR Repeal.
The sustainable-growth-rate formula (SGR) used to calculate Medicare's physician fees remains a political football. MedPAC recommends replacing it with a "predictable 10-year path" of fee-schedule upd...
